Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Anti-Human BTN3A1 (ICT 01)

Catalog #:   DHA13502 Specific References (31) DATASHEET
Host species: Humanized
Isotype: IgG1
Applications: Research Grade Biosimilar
Expression system: Mammalian Cells
Overview

Catalog No.

DHA13502

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Humanized

Isotype

IgG1

Clonality

Monoclonal

Target

BTF5, BTN3A1, Butyrophilin subfamily 3 member A1, CD277

Concentration

2.83 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

O00481

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

ICT 01, ICT-01, ICT01

Clone ID

ICT 01

Data Image
  • SEC-HPLC
    The purity of this product is >95% as determined by SEC-HPLC.
References

Mapping the extracellular molecular architecture of the pAg-signaling complex with α-Butyrophilin antibodies., PMID:40204806

Overcoming limitations for antibody-based therapies targeting γδ T (Vg9Vd2) cells., PMID:39144149

Vγ9Vδ2 T-cells Are Potent Inhibitors of SARS-CoV-2 Replication and Represent Effector Phenotypes in Patients With COVID-19., PMID:38557809

The B7:CD28 family and friends: Unraveling coinhibitory interactions., PMID:38354702

Anti-PD1 does not improve pyroptosis induced by γδ T cells but promotes tumor regression in a pleural mesothelioma mouse model., PMID:38077396

B7H3-targeting chimeric antigen receptor modification enhances antitumor effect of Vγ9Vδ2 T cells in glioblastoma., PMID:37770968

Targeting Melanoma-Associated Fibroblasts (MAFs) with Activated γδ (Vδ2) T Cells: An In Vitro Cytotoxicity Model., PMID:37629075

Caveat: Monoclonal antibodies 20.1 and 103.2 bind all human BTN3A proteins and are not suited to study BTN3A1-specific features., PMID:37155844

Priming of Colorectal Tumor-Associated Fibroblasts with Zoledronic Acid Conjugated to the Anti-Epidermal Growth Factor Receptor Antibody Cetuximab Elicits Anti-Tumor Vδ2 T Lymphocytes., PMID:36765569

The making of multivalent gamma delta TCR anti-CD3 bispecific T cell engagers., PMID:36685546

Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab., PMID:36543375

BTN3A Targeting Vγ9Vδ2 T Cells Antimicrobial Activity Against Coxiella burnetii-Infected Cells., PMID:35833118

Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application., PMID:34445615

BTN2A1, an immune checkpoint targeting Vγ9Vδ2 T cell cytotoxicity against malignant cells., PMID:34260935

Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma., PMID:33959132

γδ T cells suppress Plasmodium falciparum blood-stage infection by direct killing and phagocytosis., PMID:33432229

Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions., PMID:33178494

[Butyrophilin 3A1 (BTN3A1) enhances activation and proliferation of human peripheral blood Vγ9Vδ2 T cells induced by MTB-HAg]., PMID:32958123

BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells., PMID:32820120

Alpaca (Vicugna pacos), the first nonprimate species with a phosphoantigen-reactive Vγ9Vδ2 T cell subset., PMID:32139608

Identification of Novel T1D Risk Loci and Their Association With Age and Islet Function at Diagnosis in Autoantibody-Positive T1D Individuals: Based on a Two-Stage Genome-Wide Association Study., PMID:31152121

Regulation of Human γδ T Cells by BTN3A1 Protein Stability and ATP-Binding Cassette Transporters., PMID:29670629

The butyrophilin 3A1 intracellular domain undergoes a conformational change involving the juxtamembrane region., PMID:28705810

BTN3A1-antibodies and phosphoantigens: TCRVγ9Vδ2 "see" the difference., PMID:28597565

Butyrophilin 3A (BTN3A, CD277)-specific antibody 20.1 differentially activates Vγ9Vδ2 TCR clonotypes and interferes with phosphoantigen activation., PMID:28386905

Butyrophilin 3A/CD277-Dependent Activation of Human γδ T Cells: Accessory Cell Capacity of Distinct Leukocyte Populations., PMID:27619996

Phosphoantigens and butyrophilin 3A1 induce similar intracellular activation signaling in human TCRVγ9+ γδ T lymphocytes., PMID:24925024

Butyrophilin 3A1 plays an essential role in prenyl pyrophosphate stimulation of human Vγ2Vδ2 T cells., PMID:23833237

The molecular basis for modulation of human Vγ9Vδ2 T cell responses by CD277/butyrophilin-3 (BTN3A)-specific antibodies., PMID:22846996

Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset., PMID:22767497

Differential role for CD277 as a co-regulator of the immune signal in T and NK cells., PMID:21918970

Datasheet
$ 328
Product specifications
100 μg 328 1 mg 1314

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Anti-Human BTN3A1 (ICT 01) [DHA13502]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only